A
The company develops therapeutics that re-educate the tumor microenvironment to enhance the efficacy of standard cancer treatments and reverse resistance to checkpoint inhibitors. This approach targets the limitations of existing therapies, aiming to improve patient outcomes in oncology.
Updated 4 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The company develops therapeutics that re-educate the tumor microenvironment to enhance the efficacy of standard cancer treatments and reverse resistance to checkpoint inhibitors. This approach targets the limitations of existing therapies, aiming to improve patient outcomes in oncology.